nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCC4—Rosuvastatin—atherosclerosis	0.204	0.579	CbGbCtD
Dipyridamole—ABCB1—Ezetimibe—atherosclerosis	0.0395	0.112	CbGbCtD
Dipyridamole—ABCB1—Simvastatin—atherosclerosis	0.0367	0.104	CbGbCtD
Dipyridamole—ABCB1—Lovastatin—atherosclerosis	0.0359	0.102	CbGbCtD
Dipyridamole—ABCB1—Pravastatin—atherosclerosis	0.0359	0.102	CbGbCtD
Dipyridamole—PDE8B—leg—atherosclerosis	0.0122	0.084	CbGeAlD
Dipyridamole—PDE8B—hindlimb—atherosclerosis	0.0109	0.075	CbGeAlD
Dipyridamole—PDE8B—appendage—atherosclerosis	0.00936	0.0643	CbGeAlD
Dipyridamole—PDE5A—penis—atherosclerosis	0.00886	0.0609	CbGeAlD
Dipyridamole—PDE3A—penis—atherosclerosis	0.00862	0.0593	CbGeAlD
Dipyridamole—PDE1C—cardiovascular system—atherosclerosis	0.0047	0.0323	CbGeAlD
Dipyridamole—PDE6B—connective tissue—atherosclerosis	0.00463	0.0318	CbGeAlD
Dipyridamole—PDE5A—artery—atherosclerosis	0.0041	0.0282	CbGeAlD
Dipyridamole—PRUNE—adipose tissue—atherosclerosis	0.00374	0.0257	CbGeAlD
Dipyridamole—PDE6D—adipose tissue—atherosclerosis	0.00361	0.0248	CbGeAlD
Dipyridamole—PDE5A—endothelium—atherosclerosis	0.00346	0.0238	CbGeAlD
Dipyridamole—PDE5A—blood vessel—atherosclerosis	0.00319	0.022	CbGeAlD
Dipyridamole—PRUNE—liver—atherosclerosis	0.00262	0.018	CbGeAlD
Dipyridamole—PDE3B—connective tissue—atherosclerosis	0.00261	0.0179	CbGeAlD
Dipyridamole—PDE7B—adipose tissue—atherosclerosis	0.00257	0.0177	CbGeAlD
Dipyridamole—PDE6D—liver—atherosclerosis	0.00253	0.0174	CbGeAlD
Dipyridamole—PDE2A—cardiovascular system—atherosclerosis	0.00244	0.0167	CbGeAlD
Dipyridamole—PDE11A—liver—atherosclerosis	0.00232	0.0159	CbGeAlD
Dipyridamole—PDE3B—cardiovascular system—atherosclerosis	0.00227	0.0156	CbGeAlD
Dipyridamole—PDE6G—liver—atherosclerosis	0.00223	0.0153	CbGeAlD
Dipyridamole—PDE2A—adipose tissue—atherosclerosis	0.00215	0.0148	CbGeAlD
Dipyridamole—PDE10A—adipose tissue—atherosclerosis	0.00215	0.0148	CbGeAlD
Dipyridamole—PDE1B—adipose tissue—atherosclerosis	0.00213	0.0146	CbGeAlD
Dipyridamole—PDE8B—adipose tissue—atherosclerosis	0.00205	0.0141	CbGeAlD
Dipyridamole—PDE1A—cardiovascular system—atherosclerosis	0.00202	0.0139	CbGeAlD
Dipyridamole—PDE3B—adipose tissue—atherosclerosis	0.002	0.0138	CbGeAlD
Dipyridamole—ADA—connective tissue—atherosclerosis	0.00198	0.0136	CbGeAlD
Dipyridamole—PDE8A—adipose tissue—atherosclerosis	0.00184	0.0127	CbGeAlD
Dipyridamole—PDE7B—liver—atherosclerosis	0.0018	0.0124	CbGeAlD
Dipyridamole—PDE1A—adipose tissue—atherosclerosis	0.00178	0.0123	CbGeAlD
Dipyridamole—ADA—cardiovascular system—atherosclerosis	0.00172	0.0118	CbGeAlD
Dipyridamole—PDE5A—connective tissue—atherosclerosis	0.00164	0.0113	CbGeAlD
Dipyridamole—ADA—adipose tissue—atherosclerosis	0.00152	0.0104	CbGeAlD
Dipyridamole—PDE2A—liver—atherosclerosis	0.00151	0.0104	CbGeAlD
Dipyridamole—PDE4A—adipose tissue—atherosclerosis	0.00148	0.0102	CbGeAlD
Dipyridamole—PDE8B—liver—atherosclerosis	0.00144	0.00988	CbGeAlD
Dipyridamole—PDE5A—cardiovascular system—atherosclerosis	0.00143	0.0098	CbGeAlD
Dipyridamole—PDE3B—liver—atherosclerosis	0.0014	0.00965	CbGeAlD
Dipyridamole—PDE3A—cardiovascular system—atherosclerosis	0.00139	0.00953	CbGeAlD
Dipyridamole—SLC29A1—connective tissue—atherosclerosis	0.00138	0.00946	CbGeAlD
Dipyridamole—PDE8A—liver—atherosclerosis	0.00129	0.00889	CbGeAlD
Dipyridamole—PDE5A—adipose tissue—atherosclerosis	0.00126	0.00864	CbGeAlD
Dipyridamole—PDE1A—liver—atherosclerosis	0.00125	0.0086	CbGeAlD
Dipyridamole—PDE3A—adipose tissue—atherosclerosis	0.00122	0.0084	CbGeAlD
Dipyridamole—SLC29A1—cardiovascular system—atherosclerosis	0.0012	0.00823	CbGeAlD
Dipyridamole—ABCC5—adipose tissue—atherosclerosis	0.00115	0.0079	CbGeAlD
Dipyridamole—SLC29A1—adipose tissue—atherosclerosis	0.00106	0.00726	CbGeAlD
Dipyridamole—Cough—Rosuvastatin—atherosclerosis	0.000882	0.00362	CcSEcCtD
Dipyridamole—Angiopathy—Ezetimibe—atherosclerosis	0.000875	0.00359	CcSEcCtD
Dipyridamole—Immune system disorder—Ezetimibe—atherosclerosis	0.000871	0.00358	CcSEcCtD
Dipyridamole—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00087	0.00357	CcSEcCtD
Dipyridamole—Alopecia—Lovastatin—atherosclerosis	0.000869	0.00357	CcSEcCtD
Dipyridamole—Arthralgia—Rosuvastatin—atherosclerosis	0.00086	0.00353	CcSEcCtD
Dipyridamole—Myalgia—Rosuvastatin—atherosclerosis	0.00086	0.00353	CcSEcCtD
Dipyridamole—PDE3A—liver—atherosclerosis	0.000857	0.00589	CbGeAlD
Dipyridamole—Flushing—Simvastatin—atherosclerosis	0.000854	0.0035	CcSEcCtD
Dipyridamole—Alopecia—Ezetimibe—atherosclerosis	0.000853	0.0035	CcSEcCtD
Dipyridamole—Haemoglobin—Niacin—atherosclerosis	0.000849	0.00348	CcSEcCtD
Dipyridamole—Rhinitis—Niacin—atherosclerosis	0.000847	0.00348	CcSEcCtD
Dipyridamole—Hepatitis—Niacin—atherosclerosis	0.000845	0.00347	CcSEcCtD
Dipyridamole—Haemorrhage—Niacin—atherosclerosis	0.000845	0.00347	CcSEcCtD
Dipyridamole—Flatulence—Lovastatin—atherosclerosis	0.000844	0.00346	CcSEcCtD
Dipyridamole—Hypoaesthesia—Niacin—atherosclerosis	0.000841	0.00345	CcSEcCtD
Dipyridamole—Dysgeusia—Lovastatin—atherosclerosis	0.000839	0.00344	CcSEcCtD
Dipyridamole—Rhinitis—Pravastatin—atherosclerosis	0.000834	0.00342	CcSEcCtD
Dipyridamole—Hepatitis—Pravastatin—atherosclerosis	0.000832	0.00341	CcSEcCtD
Dipyridamole—Back pain—Lovastatin—atherosclerosis	0.000828	0.0034	CcSEcCtD
Dipyridamole—Hypoaesthesia—Pravastatin—atherosclerosis	0.000828	0.0034	CcSEcCtD
Dipyridamole—Flatulence—Ezetimibe—atherosclerosis	0.000828	0.0034	CcSEcCtD
Dipyridamole—Pharyngitis—Pravastatin—atherosclerosis	0.000826	0.00339	CcSEcCtD
Dipyridamole—Chills—Simvastatin—atherosclerosis	0.000826	0.00339	CcSEcCtD
Dipyridamole—Muscle spasms—Lovastatin—atherosclerosis	0.000823	0.00338	CcSEcCtD
Dipyridamole—Alopecia—Simvastatin—atherosclerosis	0.000813	0.00334	CcSEcCtD
Dipyridamole—Back pain—Ezetimibe—atherosclerosis	0.000812	0.00333	CcSEcCtD
Dipyridamole—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000809	0.00332	CcSEcCtD
Dipyridamole—Muscle spasms—Ezetimibe—atherosclerosis	0.000807	0.00331	CcSEcCtD
Dipyridamole—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000807	0.00331	CcSEcCtD
Dipyridamole—ABCC5—liver—atherosclerosis	0.000806	0.00554	CbGeAlD
Dipyridamole—Tremor—Lovastatin—atherosclerosis	0.000802	0.00329	CcSEcCtD
Dipyridamole—ABCC4—adipose tissue—atherosclerosis	0.000797	0.00548	CbGeAlD
Dipyridamole—Ill-defined disorder—Lovastatin—atherosclerosis	0.000795	0.00326	CcSEcCtD
Dipyridamole—Flatulence—Simvastatin—atherosclerosis	0.000789	0.00324	CcSEcCtD
Dipyridamole—Tinnitus—Niacin—atherosclerosis	0.000788	0.00323	CcSEcCtD
Dipyridamole—Dysgeusia—Simvastatin—atherosclerosis	0.000784	0.00322	CcSEcCtD
Dipyridamole—Flushing—Niacin—atherosclerosis	0.000784	0.00322	CcSEcCtD
Dipyridamole—Angioedema—Lovastatin—atherosclerosis	0.000782	0.00321	CcSEcCtD
Dipyridamole—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000779	0.0032	CcSEcCtD
Dipyridamole—Anaemia—Ezetimibe—atherosclerosis	0.000776	0.00319	CcSEcCtD
Dipyridamole—Tinnitus—Pravastatin—atherosclerosis	0.000776	0.00318	CcSEcCtD
Dipyridamole—Malaise—Lovastatin—atherosclerosis	0.000772	0.00317	CcSEcCtD
Dipyridamole—Flushing—Pravastatin—atherosclerosis	0.000772	0.00317	CcSEcCtD
Dipyridamole—Cardiac disorder—Pravastatin—atherosclerosis	0.000772	0.00317	CcSEcCtD
Dipyridamole—Muscle spasms—Simvastatin—atherosclerosis	0.00077	0.00316	CcSEcCtD
Dipyridamole—Vertigo—Lovastatin—atherosclerosis	0.000769	0.00316	CcSEcCtD
Dipyridamole—Angioedema—Ezetimibe—atherosclerosis	0.000767	0.00315	CcSEcCtD
Dipyridamole—Angiopathy—Niacin—atherosclerosis	0.000767	0.00315	CcSEcCtD
Dipyridamole—Chills—Niacin—atherosclerosis	0.000758	0.00311	CcSEcCtD
Dipyridamole—Malaise—Ezetimibe—atherosclerosis	0.000757	0.00311	CcSEcCtD
Dipyridamole—Arrhythmia—Niacin—atherosclerosis	0.000755	0.0031	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000751	0.00308	CcSEcCtD
Dipyridamole—Tremor—Simvastatin—atherosclerosis	0.00075	0.00308	CcSEcCtD
Dipyridamole—Alopecia—Niacin—atherosclerosis	0.000747	0.00306	CcSEcCtD
Dipyridamole—Chills—Pravastatin—atherosclerosis	0.000746	0.00306	CcSEcCtD
Dipyridamole—Ill-defined disorder—Simvastatin—atherosclerosis	0.000743	0.00305	CcSEcCtD
Dipyridamole—Arrhythmia—Pravastatin—atherosclerosis	0.000743	0.00305	CcSEcCtD
Dipyridamole—Palpitations—Ezetimibe—atherosclerosis	0.000742	0.00305	CcSEcCtD
Dipyridamole—Paraesthesia—Rosuvastatin—atherosclerosis	0.00074	0.00304	CcSEcCtD
Dipyridamole—Anaemia—Simvastatin—atherosclerosis	0.00074	0.00304	CcSEcCtD
Dipyridamole—SLC29A1—liver—atherosclerosis	0.00074	0.00509	CbGeAlD
Dipyridamole—Alopecia—Pravastatin—atherosclerosis	0.000735	0.00302	CcSEcCtD
Dipyridamole—Cough—Ezetimibe—atherosclerosis	0.000733	0.00301	CcSEcCtD
Dipyridamole—Angioedema—Simvastatin—atherosclerosis	0.000732	0.003	CcSEcCtD
Dipyridamole—Myalgia—Lovastatin—atherosclerosis	0.000729	0.00299	CcSEcCtD
Dipyridamole—Chest pain—Lovastatin—atherosclerosis	0.000729	0.00299	CcSEcCtD
Dipyridamole—Arthralgia—Lovastatin—atherosclerosis	0.000729	0.00299	CcSEcCtD
Dipyridamole—Anxiety—Lovastatin—atherosclerosis	0.000727	0.00298	CcSEcCtD
Dipyridamole—Dyspepsia—Rosuvastatin—atherosclerosis	0.000726	0.00298	CcSEcCtD
Dipyridamole—Hypertension—Ezetimibe—atherosclerosis	0.000725	0.00298	CcSEcCtD
Dipyridamole—Flatulence—Niacin—atherosclerosis	0.000725	0.00297	CcSEcCtD
Dipyridamole—Malaise—Simvastatin—atherosclerosis	0.000722	0.00296	CcSEcCtD
Dipyridamole—Tension—Niacin—atherosclerosis	0.000722	0.00296	CcSEcCtD
Dipyridamole—Discomfort—Lovastatin—atherosclerosis	0.00072	0.00296	CcSEcCtD
Dipyridamole—Vertigo—Simvastatin—atherosclerosis	0.00072	0.00295	CcSEcCtD
Dipyridamole—Chest pain—Ezetimibe—atherosclerosis	0.000715	0.00293	CcSEcCtD
Dipyridamole—Myalgia—Ezetimibe—atherosclerosis	0.000715	0.00293	CcSEcCtD
Dipyridamole—Arthralgia—Ezetimibe—atherosclerosis	0.000715	0.00293	CcSEcCtD
Dipyridamole—Nervousness—Niacin—atherosclerosis	0.000714	0.00293	CcSEcCtD
Dipyridamole—Flatulence—Pravastatin—atherosclerosis	0.000714	0.00293	CcSEcCtD
Dipyridamole—Dry mouth—Lovastatin—atherosclerosis	0.000713	0.00293	CcSEcCtD
Dipyridamole—Tension—Pravastatin—atherosclerosis	0.000711	0.00292	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00071	0.00291	CcSEcCtD
Dipyridamole—Dysgeusia—Pravastatin—atherosclerosis	0.000709	0.00291	CcSEcCtD
Dipyridamole—Muscle spasms—Niacin—atherosclerosis	0.000707	0.0029	CcSEcCtD
Dipyridamole—Discomfort—Ezetimibe—atherosclerosis	0.000706	0.0029	CcSEcCtD
Dipyridamole—Pain—Rosuvastatin—atherosclerosis	0.000705	0.00289	CcSEcCtD
Dipyridamole—ABCB1—blood vessel—atherosclerosis	0.000705	0.00485	CbGeAlD
Dipyridamole—Nervousness—Pravastatin—atherosclerosis	0.000703	0.00289	CcSEcCtD
Dipyridamole—Dry mouth—Ezetimibe—atherosclerosis	0.000699	0.00287	CcSEcCtD
Dipyridamole—Anaphylactic shock—Lovastatin—atherosclerosis	0.000699	0.00287	CcSEcCtD
Dipyridamole—Muscle spasms—Pravastatin—atherosclerosis	0.000696	0.00286	CcSEcCtD
Dipyridamole—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000685	0.00281	CcSEcCtD
Dipyridamole—Thrombocytopenia—Lovastatin—atherosclerosis	0.000684	0.00281	CcSEcCtD
Dipyridamole—Chest pain—Simvastatin—atherosclerosis	0.000682	0.0028	CcSEcCtD
Dipyridamole—Arthralgia—Simvastatin—atherosclerosis	0.000682	0.0028	CcSEcCtD
Dipyridamole—Myalgia—Simvastatin—atherosclerosis	0.000682	0.0028	CcSEcCtD
Dipyridamole—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00068	0.00279	CcSEcCtD
Dipyridamole—Anxiety—Simvastatin—atherosclerosis	0.00068	0.00279	CcSEcCtD
Dipyridamole—Tremor—Pravastatin—atherosclerosis	0.000678	0.00278	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000674	0.00277	CcSEcCtD
Dipyridamole—Discomfort—Simvastatin—atherosclerosis	0.000674	0.00276	CcSEcCtD
Dipyridamole—Nervous system disorder—Ezetimibe—atherosclerosis	0.000672	0.00276	CcSEcCtD
Dipyridamole—Angioedema—Niacin—atherosclerosis	0.000672	0.00276	CcSEcCtD
Dipyridamole—Ill-defined disorder—Pravastatin—atherosclerosis	0.000672	0.00276	CcSEcCtD
Dipyridamole—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000671	0.00275	CcSEcCtD
Dipyridamole—Anaemia—Pravastatin—atherosclerosis	0.000669	0.00275	CcSEcCtD
Dipyridamole—Skin disorder—Ezetimibe—atherosclerosis	0.000666	0.00273	CcSEcCtD
Dipyridamole—Angioedema—Pravastatin—atherosclerosis	0.000662	0.00271	CcSEcCtD
Dipyridamole—Vertigo—Niacin—atherosclerosis	0.000661	0.00271	CcSEcCtD
Dipyridamole—Syncope—Niacin—atherosclerosis	0.00066	0.00271	CcSEcCtD
Dipyridamole—Urticaria—Rosuvastatin—atherosclerosis	0.000655	0.00269	CcSEcCtD
Dipyridamole—Anaphylactic shock—Simvastatin—atherosclerosis	0.000654	0.00268	CcSEcCtD
Dipyridamole—Oedema—Simvastatin—atherosclerosis	0.000654	0.00268	CcSEcCtD
Dipyridamole—Malaise—Pravastatin—atherosclerosis	0.000653	0.00268	CcSEcCtD
Dipyridamole—Abdominal pain—Rosuvastatin—atherosclerosis	0.000652	0.00267	CcSEcCtD
Dipyridamole—Vertigo—Pravastatin—atherosclerosis	0.000651	0.00267	CcSEcCtD
Dipyridamole—Palpitations—Niacin—atherosclerosis	0.00065	0.00267	CcSEcCtD
Dipyridamole—Loss of consciousness—Niacin—atherosclerosis	0.000646	0.00265	CcSEcCtD
Dipyridamole—Cough—Niacin—atherosclerosis	0.000642	0.00263	CcSEcCtD
Dipyridamole—Thrombocytopenia—Simvastatin—atherosclerosis	0.00064	0.00263	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000637	0.00261	CcSEcCtD
Dipyridamole—Cough—Pravastatin—atherosclerosis	0.000632	0.00259	CcSEcCtD
Dipyridamole—Paraesthesia—Lovastatin—atherosclerosis	0.000628	0.00257	CcSEcCtD
Dipyridamole—Myalgia—Niacin—atherosclerosis	0.000626	0.00257	CcSEcCtD
Dipyridamole—Arthralgia—Niacin—atherosclerosis	0.000626	0.00257	CcSEcCtD
Dipyridamole—Hypertension—Pravastatin—atherosclerosis	0.000625	0.00257	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000625	0.00256	CcSEcCtD
Dipyridamole—Dyspnoea—Lovastatin—atherosclerosis	0.000623	0.00256	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000622	0.00255	CcSEcCtD
Dipyridamole—Chest pain—Pravastatin—atherosclerosis	0.000616	0.00253	CcSEcCtD
Dipyridamole—Arthralgia—Pravastatin—atherosclerosis	0.000616	0.00253	CcSEcCtD
Dipyridamole—Myalgia—Pravastatin—atherosclerosis	0.000616	0.00253	CcSEcCtD
Dipyridamole—Paraesthesia—Ezetimibe—atherosclerosis	0.000616	0.00253	CcSEcCtD
Dipyridamole—Dyspepsia—Lovastatin—atherosclerosis	0.000615	0.00252	CcSEcCtD
Dipyridamole—Anxiety—Pravastatin—atherosclerosis	0.000614	0.00252	CcSEcCtD
Dipyridamole—Dry mouth—Niacin—atherosclerosis	0.000612	0.00251	CcSEcCtD
Dipyridamole—Dyspnoea—Ezetimibe—atherosclerosis	0.000611	0.00251	CcSEcCtD
Dipyridamole—Discomfort—Pravastatin—atherosclerosis	0.000609	0.0025	CcSEcCtD
Dipyridamole—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000608	0.00249	CcSEcCtD
Dipyridamole—Dyspepsia—Ezetimibe—atherosclerosis	0.000603	0.00248	CcSEcCtD
Dipyridamole—Fatigue—Lovastatin—atherosclerosis	0.000603	0.00247	CcSEcCtD
Dipyridamole—Anaphylactic shock—Niacin—atherosclerosis	0.0006	0.00246	CcSEcCtD
Dipyridamole—Oedema—Niacin—atherosclerosis	0.0006	0.00246	CcSEcCtD
Dipyridamole—Pain—Lovastatin—atherosclerosis	0.000598	0.00245	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000596	0.00244	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000592	0.00243	CcSEcCtD
Dipyridamole—Asthenia—Rosuvastatin—atherosclerosis	0.000592	0.00243	CcSEcCtD
Dipyridamole—Oedema—Pravastatin—atherosclerosis	0.000591	0.00242	CcSEcCtD
Dipyridamole—Anaphylactic shock—Pravastatin—atherosclerosis	0.000591	0.00242	CcSEcCtD
Dipyridamole—Fatigue—Ezetimibe—atherosclerosis	0.000591	0.00242	CcSEcCtD
Dipyridamole—Shock—Niacin—atherosclerosis	0.000591	0.00242	CcSEcCtD
Dipyridamole—Paraesthesia—Simvastatin—atherosclerosis	0.000587	0.00241	CcSEcCtD
Dipyridamole—Pain—Ezetimibe—atherosclerosis	0.000586	0.00241	CcSEcCtD
Dipyridamole—Tachycardia—Niacin—atherosclerosis	0.000586	0.0024	CcSEcCtD
Dipyridamole—Pruritus—Rosuvastatin—atherosclerosis	0.000583	0.00239	CcSEcCtD
Dipyridamole—Skin disorder—Niacin—atherosclerosis	0.000583	0.00239	CcSEcCtD
Dipyridamole—Dyspnoea—Simvastatin—atherosclerosis	0.000583	0.00239	CcSEcCtD
Dipyridamole—Hyperhidrosis—Niacin—atherosclerosis	0.00058	0.00238	CcSEcCtD
Dipyridamole—Thrombocytopenia—Pravastatin—atherosclerosis	0.000579	0.00237	CcSEcCtD
Dipyridamole—Feeling abnormal—Lovastatin—atherosclerosis	0.000576	0.00236	CcSEcCtD
Dipyridamole—Dyspepsia—Simvastatin—atherosclerosis	0.000575	0.00236	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000571	0.00234	CcSEcCtD
Dipyridamole—Hyperhidrosis—Pravastatin—atherosclerosis	0.000571	0.00234	CcSEcCtD
Dipyridamole—Feeling abnormal—Ezetimibe—atherosclerosis	0.000565	0.00232	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000564	0.00232	CcSEcCtD
Dipyridamole—Diarrhoea—Rosuvastatin—atherosclerosis	0.000564	0.00232	CcSEcCtD
Dipyridamole—Fatigue—Simvastatin—atherosclerosis	0.000564	0.00231	CcSEcCtD
Dipyridamole—Hypotension—Niacin—atherosclerosis	0.000561	0.0023	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000561	0.0023	CcSEcCtD
Dipyridamole—Pain—Simvastatin—atherosclerosis	0.000559	0.00229	CcSEcCtD
Dipyridamole—ABCC4—liver—atherosclerosis	0.000559	0.00384	CbGeAlD
Dipyridamole—Urticaria—Lovastatin—atherosclerosis	0.000555	0.00228	CcSEcCtD
Dipyridamole—Abdominal pain—Lovastatin—atherosclerosis	0.000552	0.00227	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000547	0.00224	CcSEcCtD
Dipyridamole—Dizziness—Rosuvastatin—atherosclerosis	0.000545	0.00224	CcSEcCtD
Dipyridamole—Urticaria—Ezetimibe—atherosclerosis	0.000545	0.00223	CcSEcCtD
Dipyridamole—Abdominal pain—Ezetimibe—atherosclerosis	0.000542	0.00222	CcSEcCtD
Dipyridamole—Paraesthesia—Niacin—atherosclerosis	0.000539	0.00221	CcSEcCtD
Dipyridamole—Feeling abnormal—Simvastatin—atherosclerosis	0.000539	0.00221	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000538	0.00221	CcSEcCtD
Dipyridamole—Dyspnoea—Niacin—atherosclerosis	0.000535	0.0022	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000535	0.00219	CcSEcCtD
Dipyridamole—Somnolence—Niacin—atherosclerosis	0.000534	0.00219	CcSEcCtD
Dipyridamole—Paraesthesia—Pravastatin—atherosclerosis	0.000531	0.00218	CcSEcCtD
Dipyridamole—Dyspepsia—Niacin—atherosclerosis	0.000528	0.00217	CcSEcCtD
Dipyridamole—Dyspnoea—Pravastatin—atherosclerosis	0.000527	0.00216	CcSEcCtD
Dipyridamole—Dyspepsia—Pravastatin—atherosclerosis	0.00052	0.00213	CcSEcCtD
Dipyridamole—Rash—Rosuvastatin—atherosclerosis	0.00052	0.00213	CcSEcCtD
Dipyridamole—Dermatitis—Rosuvastatin—atherosclerosis	0.000519	0.00213	CcSEcCtD
Dipyridamole—Urticaria—Simvastatin—atherosclerosis	0.000519	0.00213	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Niacin—atherosclerosis	0.000518	0.00213	CcSEcCtD
Dipyridamole—Abdominal pain—Simvastatin—atherosclerosis	0.000517	0.00212	CcSEcCtD
Dipyridamole—Headache—Rosuvastatin—atherosclerosis	0.000517	0.00212	CcSEcCtD
Dipyridamole—Hypersensitivity—Lovastatin—atherosclerosis	0.000515	0.00211	CcSEcCtD
Dipyridamole—Pain—Niacin—atherosclerosis	0.000513	0.00211	CcSEcCtD
Dipyridamole—Fatigue—Pravastatin—atherosclerosis	0.00051	0.00209	CcSEcCtD
Dipyridamole—Pain—Pravastatin—atherosclerosis	0.000505	0.00207	CcSEcCtD
Dipyridamole—Hypersensitivity—Ezetimibe—atherosclerosis	0.000505	0.00207	CcSEcCtD
Dipyridamole—Asthenia—Lovastatin—atherosclerosis	0.000501	0.00206	CcSEcCtD
Dipyridamole—Pruritus—Lovastatin—atherosclerosis	0.000494	0.00203	CcSEcCtD
Dipyridamole—Asthenia—Ezetimibe—atherosclerosis	0.000492	0.00202	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Niacin—atherosclerosis	0.000491	0.00201	CcSEcCtD
Dipyridamole—Nausea—Rosuvastatin—atherosclerosis	0.00049	0.00201	CcSEcCtD
Dipyridamole—Feeling abnormal—Pravastatin—atherosclerosis	0.000487	0.002	CcSEcCtD
Dipyridamole—Pruritus—Ezetimibe—atherosclerosis	0.000485	0.00199	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000483	0.00198	CcSEcCtD
Dipyridamole—Hypersensitivity—Simvastatin—atherosclerosis	0.000482	0.00198	CcSEcCtD
Dipyridamole—Diarrhoea—Lovastatin—atherosclerosis	0.000478	0.00196	CcSEcCtD
Dipyridamole—Urticaria—Niacin—atherosclerosis	0.000477	0.00196	CcSEcCtD
Dipyridamole—Abdominal pain—Niacin—atherosclerosis	0.000474	0.00195	CcSEcCtD
Dipyridamole—Urticaria—Pravastatin—atherosclerosis	0.000469	0.00193	CcSEcCtD
Dipyridamole—Asthenia—Simvastatin—atherosclerosis	0.000469	0.00192	CcSEcCtD
Dipyridamole—Diarrhoea—Ezetimibe—atherosclerosis	0.000469	0.00192	CcSEcCtD
Dipyridamole—Abdominal pain—Pravastatin—atherosclerosis	0.000467	0.00192	CcSEcCtD
Dipyridamole—Pruritus—Simvastatin—atherosclerosis	0.000462	0.0019	CcSEcCtD
Dipyridamole—Dizziness—Lovastatin—atherosclerosis	0.000462	0.0019	CcSEcCtD
Dipyridamole—Dizziness—Ezetimibe—atherosclerosis	0.000453	0.00186	CcSEcCtD
Dipyridamole—Diarrhoea—Simvastatin—atherosclerosis	0.000447	0.00184	CcSEcCtD
Dipyridamole—Vomiting—Lovastatin—atherosclerosis	0.000444	0.00182	CcSEcCtD
Dipyridamole—Hypersensitivity—Niacin—atherosclerosis	0.000442	0.00181	CcSEcCtD
Dipyridamole—Rash—Lovastatin—atherosclerosis	0.000441	0.00181	CcSEcCtD
Dipyridamole—Dermatitis—Lovastatin—atherosclerosis	0.00044	0.00181	CcSEcCtD
Dipyridamole—Headache—Lovastatin—atherosclerosis	0.000438	0.0018	CcSEcCtD
Dipyridamole—Vomiting—Ezetimibe—atherosclerosis	0.000436	0.00179	CcSEcCtD
Dipyridamole—Hypersensitivity—Pravastatin—atherosclerosis	0.000435	0.00179	CcSEcCtD
Dipyridamole—Dizziness—Simvastatin—atherosclerosis	0.000432	0.00177	CcSEcCtD
Dipyridamole—Rash—Ezetimibe—atherosclerosis	0.000432	0.00177	CcSEcCtD
Dipyridamole—Dermatitis—Ezetimibe—atherosclerosis	0.000432	0.00177	CcSEcCtD
Dipyridamole—Asthenia—Niacin—atherosclerosis	0.000431	0.00177	CcSEcCtD
Dipyridamole—Headache—Ezetimibe—atherosclerosis	0.000429	0.00176	CcSEcCtD
Dipyridamole—Pruritus—Niacin—atherosclerosis	0.000425	0.00174	CcSEcCtD
Dipyridamole—Asthenia—Pravastatin—atherosclerosis	0.000424	0.00174	CcSEcCtD
Dipyridamole—Pruritus—Pravastatin—atherosclerosis	0.000418	0.00172	CcSEcCtD
Dipyridamole—Vomiting—Simvastatin—atherosclerosis	0.000416	0.00171	CcSEcCtD
Dipyridamole—Nausea—Lovastatin—atherosclerosis	0.000415	0.0017	CcSEcCtD
Dipyridamole—Rash—Simvastatin—atherosclerosis	0.000412	0.00169	CcSEcCtD
Dipyridamole—Dermatitis—Simvastatin—atherosclerosis	0.000412	0.00169	CcSEcCtD
Dipyridamole—Diarrhoea—Niacin—atherosclerosis	0.000411	0.00169	CcSEcCtD
Dipyridamole—Headache—Simvastatin—atherosclerosis	0.00041	0.00168	CcSEcCtD
Dipyridamole—Nausea—Ezetimibe—atherosclerosis	0.000407	0.00167	CcSEcCtD
Dipyridamole—Diarrhoea—Pravastatin—atherosclerosis	0.000404	0.00166	CcSEcCtD
Dipyridamole—Dizziness—Niacin—atherosclerosis	0.000397	0.00163	CcSEcCtD
Dipyridamole—Dizziness—Pravastatin—atherosclerosis	0.000391	0.0016	CcSEcCtD
Dipyridamole—Nausea—Simvastatin—atherosclerosis	0.000388	0.00159	CcSEcCtD
Dipyridamole—Vomiting—Niacin—atherosclerosis	0.000382	0.00157	CcSEcCtD
Dipyridamole—Rash—Niacin—atherosclerosis	0.000378	0.00155	CcSEcCtD
Dipyridamole—Dermatitis—Niacin—atherosclerosis	0.000378	0.00155	CcSEcCtD
Dipyridamole—Headache—Niacin—atherosclerosis	0.000376	0.00154	CcSEcCtD
Dipyridamole—Vomiting—Pravastatin—atherosclerosis	0.000376	0.00154	CcSEcCtD
Dipyridamole—Rash—Pravastatin—atherosclerosis	0.000373	0.00153	CcSEcCtD
Dipyridamole—Dermatitis—Pravastatin—atherosclerosis	0.000372	0.00153	CcSEcCtD
Dipyridamole—Headache—Pravastatin—atherosclerosis	0.00037	0.00152	CcSEcCtD
Dipyridamole—Nausea—Niacin—atherosclerosis	0.000357	0.00146	CcSEcCtD
Dipyridamole—Nausea—Pravastatin—atherosclerosis	0.000351	0.00144	CcSEcCtD
Dipyridamole—ABCB1—cardiovascular system—atherosclerosis	0.000314	0.00216	CbGeAlD
Dipyridamole—ABCB1—adipose tissue—atherosclerosis	0.000277	0.00191	CbGeAlD
Dipyridamole—ABCB1—liver—atherosclerosis	0.000194	0.00134	CbGeAlD
Dipyridamole—PDE1B—Immune System—IFNG—atherosclerosis	1.62e-05	6.26e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—MAPK3—atherosclerosis	1.62e-05	6.25e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—FABP4—atherosclerosis	1.61e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LCAT—atherosclerosis	1.61e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—STAT3—atherosclerosis	1.61e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TGFB1—atherosclerosis	1.61e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—F2—atherosclerosis	1.61e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TGFB1—atherosclerosis	1.61e-05	6.21e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—IL6—atherosclerosis	1.6e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—APOE—atherosclerosis	1.6e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—LEP—atherosclerosis	1.6e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—AKT1—atherosclerosis	1.6e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—VEGFA—atherosclerosis	1.6e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—INS—atherosclerosis	1.6e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	1.59e-05	6.14e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—IL6—atherosclerosis	1.59e-05	6.14e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CAV1—atherosclerosis	1.59e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—AKT1—atherosclerosis	1.59e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—AKT1—atherosclerosis	1.59e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—STAT3—atherosclerosis	1.59e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—APOA1—atherosclerosis	1.58e-05	6.12e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—IL6—atherosclerosis	1.58e-05	6.11e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CG—atherosclerosis	1.58e-05	6.11e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL1B—atherosclerosis	1.58e-05	6.1e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOA4—atherosclerosis	1.58e-05	6.1e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCL2—atherosclerosis	1.57e-05	6.08e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NOS3—atherosclerosis	1.57e-05	6.06e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTGS2—atherosclerosis	1.57e-05	6.06e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTGS2—atherosclerosis	1.57e-05	6.06e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—VEGFA—atherosclerosis	1.56e-05	6.03e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP7A1—atherosclerosis	1.55e-05	5.99e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IGF1—atherosclerosis	1.55e-05	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—STAT3—atherosclerosis	1.55e-05	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CG—atherosclerosis	1.54e-05	5.94e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—MAPK3—atherosclerosis	1.54e-05	5.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PDGFB—atherosclerosis	1.53e-05	5.92e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ESR1—atherosclerosis	1.53e-05	5.91e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	1.53e-05	5.9e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—MAPK3—atherosclerosis	1.52e-05	5.85e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—MAPK3—atherosclerosis	1.51e-05	5.85e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—F2—atherosclerosis	1.51e-05	5.84e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—ALB—atherosclerosis	1.5e-05	5.8e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—INS—atherosclerosis	1.5e-05	5.78e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AGT—atherosclerosis	1.5e-05	5.78e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TGFB1—atherosclerosis	1.49e-05	5.76e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—AKT1—atherosclerosis	1.49e-05	5.75e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—AKT1—atherosclerosis	1.48e-05	5.71e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—MAPK3—atherosclerosis	1.48e-05	5.7e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—NFKB1—atherosclerosis	1.47e-05	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—MAPK3—atherosclerosis	1.47e-05	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCL2—atherosclerosis	1.47e-05	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TGFB1—atherosclerosis	1.47e-05	5.68e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—SERPINE1—atherosclerosis	1.47e-05	5.67e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	1.47e-05	5.67e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—APOE—atherosclerosis	1.47e-05	5.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—LEP—atherosclerosis	1.47e-05	5.66e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—AKT1—atherosclerosis	1.47e-05	5.66e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—IL6—atherosclerosis	1.46e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—IL6—atherosclerosis	1.46e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—AKT1—atherosclerosis	1.46e-05	5.64e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—INS—atherosclerosis	1.46e-05	5.62e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—IL6—atherosclerosis	1.45e-05	5.61e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CAV1—atherosclerosis	1.45e-05	5.61e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—MAPK8—atherosclerosis	1.45e-05	5.6e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—APOA1—atherosclerosis	1.45e-05	5.6e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IGF1—atherosclerosis	1.45e-05	5.59e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CG—atherosclerosis	1.45e-05	5.59e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	1.45e-05	5.59e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL1B—atherosclerosis	1.45e-05	5.58e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—NOS3—atherosclerosis	1.44e-05	5.55e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTGS2—atherosclerosis	1.43e-05	5.54e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP27A1—atherosclerosis	1.43e-05	5.54e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCL2—atherosclerosis	1.43e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TGFB1—atherosclerosis	1.43e-05	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—IL6—atherosclerosis	1.42e-05	5.5e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IGF1—atherosclerosis	1.41e-05	5.44e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	1.41e-05	5.43e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	1.4e-05	5.42e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NOS3—atherosclerosis	1.4e-05	5.42e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ESR1—atherosclerosis	1.4e-05	5.41e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—MAPK3—atherosclerosis	1.39e-05	5.35e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—F2—atherosclerosis	1.38e-05	5.34e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—SERPINE1—atherosclerosis	1.38e-05	5.31e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—INS—atherosclerosis	1.37e-05	5.29e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOA2—atherosclerosis	1.36e-05	5.25e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PLA2G2A—atherosclerosis	1.36e-05	5.25e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALOX5AP—atherosclerosis	1.36e-05	5.25e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALOX15—atherosclerosis	1.36e-05	5.25e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—AKT1—atherosclerosis	1.35e-05	5.21e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—AKT1—atherosclerosis	1.35e-05	5.21e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—NFKB1—atherosclerosis	1.35e-05	5.21e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCL2—atherosclerosis	1.35e-05	5.2e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ABCG5—atherosclerosis	1.34e-05	5.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—AKT1—atherosclerosis	1.34e-05	5.18e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—SERPINE1—atherosclerosis	1.34e-05	5.17e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK8—atherosclerosis	1.33e-05	5.12e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—STAT3—atherosclerosis	1.32e-05	5.12e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IGF1—atherosclerosis	1.32e-05	5.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CG—atherosclerosis	1.32e-05	5.11e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—AKT1—atherosclerosis	1.31e-05	5.08e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTGS2—atherosclerosis	1.31e-05	5.07e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NOS3—atherosclerosis	1.31e-05	5.07e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	1.31e-05	5.06e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—IL6—atherosclerosis	1.3e-05	5.03e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LPA—atherosclerosis	1.3e-05	5.01e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NOS3—atherosclerosis	1.28e-05	4.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—MAPK3—atherosclerosis	1.27e-05	4.89e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—MAPK3—atherosclerosis	1.27e-05	4.89e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SERPINE1—atherosclerosis	1.26e-05	4.86e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—BGN—atherosclerosis	1.26e-05	4.85e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—INS—atherosclerosis	1.25e-05	4.84e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CXCL8—atherosclerosis	1.24e-05	4.8e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOA5—atherosclerosis	1.24e-05	4.8e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCL2—atherosclerosis	1.23e-05	4.76e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—STAT3—atherosclerosis	1.22e-05	4.72e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—STAT3—atherosclerosis	1.22e-05	4.72e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—STAT3—atherosclerosis	1.21e-05	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—atherosclerosis	1.21e-05	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—atherosclerosis	1.21e-05	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IGF1—atherosclerosis	1.21e-05	4.68e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—atherosclerosis	1.2e-05	4.64e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—atherosclerosis	1.2e-05	4.64e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NOS3—atherosclerosis	1.2e-05	4.64e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.2e-05	4.62e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.19e-05	4.58e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—atherosclerosis	1.18e-05	4.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MAPK3—atherosclerosis	1.17e-05	4.51e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MAPK3—atherosclerosis	1.17e-05	4.51e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CXCL8—atherosclerosis	1.16e-05	4.5e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK3—atherosclerosis	1.16e-05	4.47e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALOX5—atherosclerosis	1.16e-05	4.46e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SERPINE1—atherosclerosis	1.15e-05	4.44e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TGFB1—atherosclerosis	1.13e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TGFB1—atherosclerosis	1.13e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CXCL8—atherosclerosis	1.13e-05	4.38e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—atherosclerosis	1.13e-05	4.36e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—atherosclerosis	1.13e-05	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—atherosclerosis	1.13e-05	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—atherosclerosis	1.12e-05	4.34e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—STAT3—atherosclerosis	1.12e-05	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—atherosclerosis	1.12e-05	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—atherosclerosis	1.12e-05	4.32e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NFKB1—atherosclerosis	1.11e-05	4.3e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.11e-05	4.29e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—atherosclerosis	1.11e-05	4.28e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—atherosclerosis	1.11e-05	4.28e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NOS3—atherosclerosis	1.1e-05	4.24e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—atherosclerosis	1.09e-05	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK8—atherosclerosis	1.09e-05	4.23e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—atherosclerosis	1.09e-05	4.21e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—atherosclerosis	1.08e-05	4.17e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—atherosclerosis	1.08e-05	4.16e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MAPK3—atherosclerosis	1.07e-05	4.13e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CXCL8—atherosclerosis	1.07e-05	4.11e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—atherosclerosis	1.05e-05	4.07e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NFKB1—atherosclerosis	1.04e-05	4.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—TGFB1—atherosclerosis	1.04e-05	4e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NAMPT—atherosclerosis	1.04e-05	4e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—atherosclerosis	1.04e-05	4e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LIPC—atherosclerosis	1.03e-05	3.98e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—atherosclerosis	1.03e-05	3.97e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—atherosclerosis	1.02e-05	3.96e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK8—atherosclerosis	1.02e-05	3.96e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOC3—atherosclerosis	1.02e-05	3.95e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—atherosclerosis	1.02e-05	3.95e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—atherosclerosis	1.02e-05	3.95e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LDLR—atherosclerosis	1.02e-05	3.93e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NFKB1—atherosclerosis	1.01e-05	3.92e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—atherosclerosis	1.01e-05	3.91e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—atherosclerosis	1.01e-05	3.9e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STAT3—atherosclerosis	1e-05	3.86e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK8—atherosclerosis	9.97e-06	3.85e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—atherosclerosis	9.96e-06	3.85e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—atherosclerosis	9.94e-06	3.84e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CETP—atherosclerosis	9.94e-06	3.84e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	9.76e-06	3.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CXCL8—atherosclerosis	9.74e-06	3.76e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—atherosclerosis	9.63e-06	3.72e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK3—atherosclerosis	9.56e-06	3.69e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NFKB1—atherosclerosis	9.53e-06	3.68e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SCARB1—atherosclerosis	9.52e-06	3.67e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—atherosclerosis	9.46e-06	3.65e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—atherosclerosis	9.41e-06	3.63e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK8—atherosclerosis	9.37e-06	3.62e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STAT3—atherosclerosis	9.37e-06	3.62e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—atherosclerosis	9.34e-06	3.61e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TGFB1—atherosclerosis	9.27e-06	3.58e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—atherosclerosis	9.26e-06	3.58e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—atherosclerosis	9.25e-06	3.57e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—atherosclerosis	9.2e-06	3.55e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STAT3—atherosclerosis	9.11e-06	3.52e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—atherosclerosis	9.09e-06	3.51e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HMGCR—atherosclerosis	8.99e-06	3.47e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK3—atherosclerosis	8.95e-06	3.46e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—atherosclerosis	8.81e-06	3.4e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	8.81e-06	3.4e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NFKB1—atherosclerosis	8.72e-06	3.37e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK3—atherosclerosis	8.7e-06	3.36e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TGFB1—atherosclerosis	8.68e-06	3.35e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—atherosclerosis	8.65e-06	3.34e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK8—atherosclerosis	8.57e-06	3.31e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STAT3—atherosclerosis	8.57e-06	3.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—atherosclerosis	8.55e-06	3.3e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—atherosclerosis	8.54e-06	3.3e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—atherosclerosis	8.54e-06	3.3e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—atherosclerosis	8.54e-06	3.3e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—atherosclerosis	8.46e-06	3.27e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TGFB1—atherosclerosis	8.45e-06	3.26e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK3—atherosclerosis	8.18e-06	3.16e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ABCA1—atherosclerosis	8.01e-06	3.09e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TGFB1—atherosclerosis	7.94e-06	3.07e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—atherosclerosis	7.91e-06	3.06e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—atherosclerosis	7.88e-06	3.04e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—atherosclerosis	7.88e-06	3.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STAT3—atherosclerosis	7.83e-06	3.03e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—atherosclerosis	7.81e-06	3.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—atherosclerosis	7.81e-06	3.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK3—atherosclerosis	7.49e-06	2.89e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TGFB1—atherosclerosis	7.26e-06	2.8e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—atherosclerosis	7.21e-06	2.78e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—atherosclerosis	6.99e-06	2.7e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HMOX1—atherosclerosis	6.87e-06	2.65e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—atherosclerosis	6.6e-06	2.55e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOB—atherosclerosis	6.58e-06	2.54e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—atherosclerosis	6.54e-06	2.53e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—atherosclerosis	6.45e-06	2.49e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTM1—atherosclerosis	6.4e-06	2.47e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—atherosclerosis	6.36e-06	2.46e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—LPL—atherosclerosis	6.28e-06	2.43e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GPX1—atherosclerosis	6.13e-06	2.37e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—atherosclerosis	6.04e-06	2.33e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—atherosclerosis	5.98e-06	2.31e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CD36—atherosclerosis	5.97e-06	2.31e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—atherosclerosis	5.87e-06	2.27e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—MTHFR—atherosclerosis	5.66e-06	2.19e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARA—atherosclerosis	5.55e-06	2.14e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—atherosclerosis	5.52e-06	2.13e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—atherosclerosis	5.47e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AGT—atherosclerosis	5.38e-06	2.08e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOE—atherosclerosis	5.27e-06	2.03e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CAV1—atherosclerosis	5.22e-06	2.02e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—APOA1—atherosclerosis	5.21e-06	2.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—atherosclerosis	5.05e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.75e-06	1.84e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—atherosclerosis	4.59e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—INS—atherosclerosis	4.5e-06	1.74e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALB—atherosclerosis	4.13e-06	1.59e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NOS3—atherosclerosis	3.95e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—atherosclerosis	3.61e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—atherosclerosis	1.81e-06	7.01e-06	CbGpPWpGaD
